دورية أكاديمية
أعرض في EDS

Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017.

التفاصيل البيبلوغرافية
العنوان: Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017.
المؤلفون: Yade MS; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal. borombakh66@gmail.com.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal. borombakh66@gmail.com., Dièye B; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal., Coppée R; Université Paris Cité and Sorbonne Paris Nord, Inserm, IAME, 75018, Paris, France., Mbaye A; Université Gamal Abdel Nasser de Conakry/Centre for Research and Training in Infectiology of Guinea (CERFIG), Conakry, Guinea., Diallo MA; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal., Diongue K; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal.; Service of Parasitology-Mycology, Faculty of Medecine, Pharmacy, and Odontostomatology, Cheikh Anta Diop University of Dakar, Dakar, 10700, Senegal., Bailly J; Université Paris Cité, IRD, MERIT, 75006, Paris, France., Mama A; Université de Paris, Institut Cochin, Inserm U1016, Service de Parasitologie Hôpital Cochin, 75014, Paris, France., Fall A; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal., Thiaw AB; Department of Biochemistry and Functional Genomics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Canada., Ndiaye IM; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal., Ndiaye T; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal., Gaye A; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal., Tine A; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal., Diédhiou Y; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal., Mbaye AM; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal., Doderer-Lang C; Université de Strasbourg, Institute of Parasitology and Tropical Diseases, UR7292 Dynamics of Host-Pathogen Interactions, 67000, Strasbourg, France., Garba MN; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal., Bei AK; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, 02115, USA., Ménard D; Université de Strasbourg, Institute of Parasitology and Tropical Diseases, UR7292 Dynamics of Host-Pathogen Interactions, 67000, Strasbourg, France.; CHU Strasbourg, Laboratory of Parasitology and Medical Mycology, 67000, Strasbourg, France.; Institut Pasteur, Université Paris Cité, Malaria Genetics and Resistance Unit, INSERM U1201, 75015, Paris, France.; Institut Pasteur, Université de Paris, Malaria Parasite Biology and Vaccines Unit, Paris, France., Ndiaye D; Laboratory of Parasitology-Mycology, Aristide le Dantec Hospital, Université Cheikh Anta Diop, Dakar, Senegal.; International Research Training Center on Genomics and Health Surveillance (CIGASS), Dakar, Senegal.; Service of Parasitology-Mycology, Faculty of Medecine, Pharmacy, and Odontostomatology, Cheikh Anta Diop University of Dakar, Dakar, 10700, Senegal.
المصدر: Malaria journal [Malar J] 2023 May 26; Vol. 22 (1), pp. 167. Date of Electronic Publication: 2023 May 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101139802 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2875 (Electronic) Linking ISSN: 14752875 NLM ISO Abbreviation: Malar J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2002-
مواضيع طبية MeSH: Parasites* , Antimalarials*/pharmacology , Antimalarials*/therapeutic use , Malaria, Falciparum*/parasitology , Artemisinins*/pharmacology , Artemisinins*/therapeutic use, Animals ; Humans ; Senegal ; Drug Resistance/genetics ; Plasmodium falciparum ; Uganda ; Protozoan Proteins/genetics ; Protozoan Proteins/therapeutic use ; High-Throughput Nucleotide Sequencing ; Mutation
مستخلص: Background: Malaria control is highly dependent on the effectiveness of artemisinin-based combination therapy (ACT), the current frontline malaria curative treatment. Unfortunately, the emergence and spread of parasites resistant to artemisinin (ART) derivatives in Southeast Asia and South America, and more recently in Rwanda and Uganda (East Africa), compromise their long-term use in sub-Saharan Africa, where most malaria deaths occur.
Methods: Here, ex vivo susceptibility to dihydroartemisinin (DHA) was evaluated from 38 Plasmodium falciparum isolates collected in 2017 in Thiès (Senegal) expressed in the Ring-stage Survival Assay (RSA). Both major and minor variants were explored in the three conserved-encoding domains of the pfkelch13 gene, the main determinant of ART resistance using a targeted-amplicon deep sequencing (TADS) approach.
Results: All samples tested in the ex vivo RSA were found to be susceptible to DHA (parasite survival rate < 1%). The non-synonymous mutations K189T and K248R in pfkelch13 were observed each in one isolate, as major (99%) or minor (5%) variants, respectively.
Conclusion: The results suggest that ART is still fully effective in the Thiès region of Senegal in 2017. Investigations combining ex vivo RSA and TADS are a useful approach for monitoring ART resistance in Africa.
(© 2023. The Author(s).)
التعليقات: Update of: Res Sq. 2023 Feb 06:rs.3.rs-2538775. doi: 10.21203/rs.3.rs-2538775/v1. (PMID: 36798264)
References: Genome Med. 2017 Jan 24;9(1):5. (PMID: 28118860)
Nat Med. 2020 Oct;26(10):1602-1608. (PMID: 32747827)
Lancet Infect Dis. 2021 Apr;21(4):e82-e92. (PMID: 33125913)
N Engl J Med. 2018 Nov 15;379(20):1962-1964. (PMID: 30428283)
Int J Parasitol Drugs Drug Resist. 2013 Aug 12;3:135-42. (PMID: 24533303)
Antimicrob Agents Chemother. 2015 Aug;59(8):5061-4. (PMID: 26033725)
Sci Rep. 2020 Jun 1;10(1):8907. (PMID: 32483161)
N Engl J Med. 2009 Jul 30;361(5):455-67. (PMID: 19641202)
Sci Rep. 2019 Jul 23;9(1):10675. (PMID: 31337835)
Antimicrob Agents Chemother. 2015 Oct 26;60(1):624-7. (PMID: 26503652)
Clin Infect Dis. 2022 Sep 30;75(7):1242-1244. (PMID: 35213688)
Antimicrob Agents Chemother. 2015 Jan;59(1):326-30. (PMID: 25348538)
Lancet Infect Dis. 2021 Aug;21(8):1120-1128. (PMID: 33864801)
BMC Infect Dis. 2020 Jul 22;20(1):533. (PMID: 32698879)
Antimicrob Agents Chemother. 2019 Oct 22;63(11):. (PMID: 31427297)
J Infect Dis. 2022 Apr 19;225(8):1411-1414. (PMID: 34216470)
J Infect Dis. 2021 Mar 29;223(6):985-994. (PMID: 33146722)
Malar J. 2020 May 24;19(1):191. (PMID: 32448203)
Nature. 2014 Jan 2;505(7481):50-5. (PMID: 24352242)
Emerg Infect Dis. 2021 Jan;27(1):294-296. (PMID: 33350925)
Lancet Infect Dis. 2018 Mar;18(3):337-345. (PMID: 29398391)
Emerg Infect Dis. 2018 Apr;24(4):718-726. (PMID: 29553316)
Malar J. 2021 Jun 22;20(1):275. (PMID: 34158055)
Malar J. 2020 Mar 30;19(1):134. (PMID: 32228566)
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0132021. (PMID: 34606334)
Antimicrob Agents Chemother. 2017 Feb 23;61(3):. (PMID: 28069653)
PLoS One. 2021 Mar 26;16(3):e0249357. (PMID: 33770151)
Lancet Infect Dis. 2013 Dec;13(12):1043-9. (PMID: 24035558)
Malar J. 2016 Nov 26;15(1):572. (PMID: 27887614)
Malar J. 2014 Dec 04;13:472. (PMID: 25471113)
N Engl J Med. 2021 Sep 23;385(13):1163-1171. (PMID: 34551228)
معلومات مُعتمدة: U19 AI089696 United States AI NIAID NIH HHS; ANR-11-15 LABX-0024-PARAFRAP Institut Pasteur, Paris, the French Government (Agence Nationale de la Recherche), Laboratoire d'Excellence (LabEx) "French Parasitology Alliance for Health Care"; U19AI089696 International Centers of Excellence for Malaria Research (ICEMR), West Africa; ANR Chrono ANR-19-CE35-0009 Cochin institute
فهرسة مساهمة: Keywords: Artemisinin partial resistance; Malaria; Pfkelch13 genotype; Plasmodium falciparum; Ring-stage Survival Assay; Senegal; Targeted-amplicon deep sequencing
المشرفين على المادة: 0 (Antimalarials)
9RMU91N5K2 (artemisinin)
6A9O50735X (artenimol)
0 (Artemisinins)
0 (Protozoan Proteins)
تواريخ الأحداث: Date Created: 20230526 Date Completed: 20230529 Latest Revision: 20240626
رمز التحديث: 20240626
مُعرف محوري في PubMed: PMC10223908
DOI: 10.1186/s12936-023-04588-1
PMID: 37237307
قاعدة البيانات: MEDLINE
الوصف
تدمد:1475-2875
DOI:10.1186/s12936-023-04588-1